Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Atika Capital Management LLC

Atika Capital Management LLC decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 19.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,206 shares of the biopharmaceutical company’s stock after selling 5,494 shares during the period. Atika Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $10,126,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ALNY. Root Financial Partners LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. Atlantic Union Bankshares Corp purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $30,000. Ameriflex Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $32,000. Finally, ORG Partners LLC raised its stake in shares of Alnylam Pharmaceuticals by 70.2% during the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 33 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.6%

Shares of ALNY stock opened at $320.43 on Thursday. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company’s 50-day moving average price is $347.70 and its 200-day moving average price is $411.60. The stock has a market cap of $42.50 billion, a price-to-earnings ratio of 187.39 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the business posted ($0.65) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Morgan Stanley cut their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Finally, Royal Bank Of Canada reduced their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the sale, the executive vice president owned 21,860 shares of the company’s stock, valued at $6,989,297.80. This trade represents a 7.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 6,799 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the sale, the chief executive officer owned 98,628 shares in the company, valued at $32,315,464.20. This represents a 6.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 53,923 shares of company stock worth $18,072,087. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.